Haematologica. Open access journal of the Ferrata-Storti Foundation, a no profit organization
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Haematologica. Open access journal of the Ferrata-Storti Foundation, a no profit organization
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
  • Home
  • Current Issue
  • Early view
  • Review Series
  • Archive
  • About Us
    About Haematologica Editorial Team Our Policies Advertising Rights & Permissions Contact
  • Haematologica Award
    How to participate 2025 Winners
  • Submit a Manuscript
    Author Guidelines Reviewer Guidelines Submit and Track Manuscript Track Manuscript submitted before October 1st, 2025
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Search results are limited to:
Abstract Book of the 7th European Myeloma Network Meeting, Prague, 16-18 April 2026
Vol. 111 No. s2
Search articles for: 
Showing matches for the individual search terms you entered. To search for an exact phrase, enclose your query in quotes.
Advanced filters
Search the full archive
Keyword matches

P30 | PROGNOSTIC IMPACT OF THE LYMPHOCYTE-TO-ALBUMIN RATIO IN PATIENTS WITH MULTIPLE MYELOMA (238 Online Views)

G.A. Cagliyan

Pamukkale University Department of Hematology, Denizli, Turkey
Lymphocyte-to-albumin ratio Prognostic biomarkers Multiple Myeloma

P44 | EARLIER USE OF CILTACABTAGENE AUTOLEUCEL IS ASSOCIATED WITH BETTER IMMUNE FITNESS AND STRONGER IMMUNE EFFECTS AS SHOWN BY CORRELATIVE ANALYSIS OF PERIPHERAL BLOOD AND THE BONE MARROW TUMOR MICROENVIRONMENT FROM THE CARTITUDE-4 STUDY (331 Online Views)

N.W.C.J. Van De Donk1, S. Parekh2, K. Li3, Y. Lin4, T.G. Martin5, S. Han2, R. Montes De Oca2, M. Suraneni3, M. Gormley2, B. Hodkinson2, J. Yuan2, F. Wang3, A. Kumar2, D. Yin2, D. Smirnov2, J. Patel2, N. Lendvai3, D. Madduri3, J. Zhu6, M. Koneru6, N. Patel6, D. Geng6, V. Plaks2, S. Harrison7|8|9

1 Vrije Universiteit Amsterdam, The Netherlands
2 Icahn School of Medicine at Mount Sinai, New York, USA
3 Johnson & Johnson
4 Mayo Clinic, Rochester, USA
5 University of California San Francisco, USA
6 Legend Biotech USA Inc, Somerset, USA
7 Peter MacCallum Cancer Centre, Melbourne, Australia
8 Royal Melbourne Hospital, Australia
9 University of Melbourne, Parkville, Australia
CARTITUDE-4 Prognostic Biomarkers RRMM
Title matches

B02 | THE PROGNOSTIC IMPACT OF BONE MARROW PLASMA CELL INFILTRATION AT DIAGNOSIS IN AL AMYLOIDOSIS (391 Online Views)

K. Aslantaş1, Ş. Özlü2, I. Kuzu2, M. Beksaç3|4, G. Cengiz Seval4

1 Department of Internal Medicine, Ankara University Faculty of Medicine, Turkey
2 Department of Pathology, Ankara University Faculty of Medicine, Turkey
3 Istinye University, Ankara Liv Hospital, Turkey
4 Department of Hematology, Ankara University Faculty of Medicine, Turkey
AL amyloidosis BMPC Turkey

P16 | INTEGRATED p53 ISOFORM EXPRESSION DEFINES NOVEL PROGNOSTIC SUBGROUPS IN MULTIPLE MYELOMA (271 Online Views)

E. Borsi1, A. Vitale2, V. Solli2, V. Meixian Vuong2, M. Martello1, I. Vigliotta1, S. Armuzzi2, A. Poletti2, B. Taurisano2, A. Varacalli1|2, G. Mazzocchetti2, A. Croce2, I. Pistis1, E. Zamagni2|1, P. Tacchetti1, I. Rizzello1|2, M. Cavo2, C. Terragna1

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
2 DIMEC – Dipartimento di Medicina e Chirurgia, Università di Bologna, Italy
p53 isoform Multiple Myeloma Prognostic Factors

P31 | PROGNOSTIC IMPACT OF INTERPHASE FISH IN MULTIPLE MYELOMA: SINGLE-CENTER IRISH EXPERIENCE (247 Online Views)

T. Pramod1, A. Bannaga1, S. Kumar1, B. Hennessy1, E. E. Hassadi1

1 University Hospital Waterford, Ireland
Multiple Myeloma Prognostic factors FISH abnormalities

P21 | THE LONG TERM PROGNOSTIC IMPACT OF CHROMOSOME 1 ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS (278 Online Views)

N. Iannozzi1, G. Sammarelli2, G. Todaro2, A. Poletti1, M. Scita2, B. D. Palma2, M. Bernardi2, C. Sitzia1, N. Giuliani1|2|3

1 University of Parma, Italy
2 Hematology Unit-University Hospital of Parma, Italy
3 Multiple myeloma and monoclonal gammopathies program, University Hospital of Parma, Italy
Multiple Myeloma Chromosome 1 abnormalities NDMM

B07 | PROGNOSTIC ROLE OF STANDARDIZED (18)F-FDG-PET/CT AND WB-DW-MRI IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS RECEIVING T CELL-REDIRECTING THERAPIES (391 Online Views)

M. Talarico1|2, A. Cattabriga1|3, L. Pagnini1|4, V. Solli1|2, S. Barbato1|2, S. Ghibellini1|2, S. Masci1|2, E. Manzato1|2, M. Puppi1|2, M. Iezza1|2, K. Mancuso1|2, L. Pantani2, P. Tacchetti2, C. Terragna2, M. Ursi5, E. Maffini5, F. Bonifazi5, S. Brocchi3, C. Mosconi1|3, C. Nanni4, S. Fanti1|4, E. Zamagni1|2

1 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy
2 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
3 Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
4 Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
5 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
RRMM Functional Imaging T-cell Therapy
Text matches

P01 | CIRCULATING TUMOR CELLS IMPROVE RISK STRATIFICATION ACCORDING TO THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM AND THE IMS-IMWG CONSENSUS GENOMIC STAGING IN NDMM PATIENTS. AN ANALYSIS FROM THE EUROPEAN CTC CONSORTIUM (320 Online Views)

First match: Background. Circulating tumor plasma cells (CTCs) are independent prognostic biomarkers in NDMM patients (pts), but their relevance in the context of R2-ISS and the new I ...

M. D’Agostino1, E. Martín-Sánchez2, D. Žihala3|4, I. Kostopoulos5, J.J. Garcés6, N. Puig7, G. Bertuglia1, T. Ševčíková3, T. Cupedo8, M. Van Duin8, J. Keats9, E. Zamagni10|11, P. Moreau12, S. Zweegman13, B. Van Der Holt8|14, D. Hofste Op Bruinink8, E. Dama15, J. Corre16, M. Boccadoro15, M.A. Dimopoulos17|18, R. Hájek3|4, B. Paiva2, P. Sonneveld8|19, A. Broijl8, E. Terpos17, T. Jelínek3|4, J. San-Miguel2, F. Gay1, L. Bertamini8

1 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Italy
2 Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain
3 Department of Hematooncology, University Hospital Ostrava, Czech Republic
4 Department of Hematooncology, Faculty of Medicine, University of Ostrava, Czech Republic
5 School of Science, National and Kapodistrian University of Athens, Greece
6 Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, USA
7 Hospital Universitario Salamanca, Spain
8 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
9 Clinical Genomics and Therapeutics Division, Translational Genomics Research Institute, Phoenix, USA
10 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Italy
11 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy
12 Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
13 Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit, The Netherlands
14 HOVON Foundation, Rotterdam, The Netherlands
15 European Myeloma Network, Italy
16 Unité de Génomique du Myélome, University Hospital, IUCT-Oncopole, CRCT, Toulouse, France
17 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece
18 Department of Medicine, Korea University, Seoul, Korea
19 European Myeloma Network, The Netherlands
Circulating Tumor Plasma Cells NDMM European CTC Consortium.

P11 | PERIPHERAL MEASURABLE RESIDUAL DISEASE ACTIVITY ASSESSMENT BY MALDI-TOF MASS SPECTROMETRY IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA IN THE PHASE 3 GMMG-HD7 TRIAL (327 Online Views)

First match: ... ed minimal residual disease (MRD) has emerged as one of the strongest surrogate biomarkers for progression-free (PFS) and overall survival (OS). However, MRD assessment r ...

J.X. Jin1, V.R. Ginde2, S. Huhn1|3, P.. Reichert1|3, U. Bertsch1|3, R. Fenk4, B. Besemer5, A. Boquoi6, R. Schroers7, I. Von Metzler8, M. Hänel9, C.. Mann10, L.B. Leypoldt11, B. Heilmeier12, C. Scheid13, T. Peters-Regehr14, I.W. Blau15, C. Müller-Tidow1, S. Luntz16, T.A.W. Holderried17, K. Trautmann-Grill18, D. Gezer19, M. Klaiber-Hakimi20, M. Müller21, E. Shumilov22, W. Knauf23, C.S. Michel24, T. Geer25, H. Riesenberg26, C.. Lutz27, M.S. Raab1, N. Weinhold1, M. Hoffmann28, A. Benner2, P. Findeisen29, K.C. Weisel11, H.J. Salwender30, H. Goldschmidt1|3, E.K. Mai1

1 Heidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group GMMG, Heidelberg University Hospital and Medical Faculty Heidelberg, Germany
2 Division of Biostatistics, German Cancer Research Center
3 National Center for Tumor Diseases Heidelberg, Germany
4 Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Germany
5 Department of Internal Medicine II, University Hospital Tübingen, Germany
6 Department for Hematology and Stem Cell Transplantation, University Hospital Essen, Germany
7 Department of Hematology and Oncology, Knappschaft Kliniken, Ruhr-University Bochum, Germany
8 Department of Medicine II-Hematology and Oncology, Goethe-University Frankfurt, University Hospital, Frankfurt am Main, Germany
9 Department of Internal Medicine III, Klinikum Chemnitz, Germany
10 Department for Hematology, Oncology and Immunology, University Hospital Giessen and Marburg, Marburg, Germany
11 Department of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
12 Clinic for Oncology and Hematology, Hospital Barmherzige Brueder Regensburg, Germany
13 Department of Internal Medicine I, University Hospital Cologne, Germany
14 The Binding Site GmbH, part of Thermo Fisher Scientific, Schwetzingen, Germany
15 Medical Clinic, Charité University Medicine Berlin, Germany
16 Coordination Centre for Clinical Trials-KKS, University Hospital and Medical Faculty Heidelberg, Germany
17 Department of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn, Germany
18 Department of Internal Medicine I, University Hospital Dresden, Germany
19 Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Germany
20 Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Germany
21 Clinic for Hematology, Oncology and Immunology, Klinikum Siloah Hannover, Germany
22 Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Germany
23 Center for Hematology and Oncology Bethanien, Frankfurt am Main, Germany
24 Department of Internal Medicine III, University Hospital Mainz, Germany
25 Department of Internal Medicine III, Diakoneo Clinic Schwäbisch-Hall, Schwäbisch-Hall, Germany
26 Hematology/Oncology Center, Bielefeld, Germany
27 Hematology/Oncology Center, Koblenz, Germany
28 Medical Clinic A, Clinic Ludwigshafen, Germany
29 MVZ Labor Dr. Limbach und Kollegen, Heidelberg, Germany
30 Asklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Germany. °For The German-Speaking Myeloma Multicenter Group. *Contributed equally as senior authors. *Hd7 Investigators
MALDI-TOF Minimal Residual Disease Multiple Myeloma

P20 | INFLAMMATION SCORE (I-SCORE) IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A NEW EASY TOOL TO ASSESS PROGNOSIS (283 Online Views)

First match: ... en (Fb) and Ferritin (Fe). However, the relationship between these inflammatory biomarkers and the prognosis of MM is still unknown.Objectives. To provide an easy and cos ...

V. Bongarzoni1, B. Anaclerico1, G. Tomei2, S. Morè3, F. Di Landro4, F. Fazio5, F. Fioritoni6, G. Antolino7, S. Gentili8, L. De Padua9, L. Cupelli10, S. Gumenyuk11, M. Di Cecca12, M. Garzia13, L. Fiori14, A. Rago15, P. Arcuri4, E. Rossi4, M. Capriata5, M. Offidani3, A. Andriani2, R. Latagliata2

1 UOC Hematology, San Giovanni-Addolorata Hospital, Rome, Italy
2 UOC Hematology - ASL Viterbo – Santa Rosa Hospital, Italy
3 Hematology Clinic, AOU delle Marche, Ancona, Italy
4 Hematology Clinic, Policlinico Agostino Gemelli, Rome, Italy
5 Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, Italy
6 Hematology Unit, Pescara Hospital, Italy
7 Hematology, Sant’Andrea Hospital, Rome, Italy
8 UOSD Ematologia Civitanova Marche AST, Macerata, Italy
9 UOC di Ematologia, Trapianto di Cellule Staminali e Terapia Genica, Frosinone, Italy
10 UOC Hematology, Sant’Eugenio Hospital, Rome, Italy
11 Hematolgy Unit IRCCS Regina Elena National Cancer Institute, Rome, Italy
12 UOC Hematology Campus Biomedico, Rome, Italy
13 UOC Hematology and stem cell transplant, San Camillo Hospital, Rome, Italy
14 UOC Hematology Santa Maria Goretti,Hospital, Latina, Italy
15 UOSD Ematologia ASL Roma1, Rome, Italy
Multiple Myeloma Elderly Inflammation Score

P73 | TP53 MUTATION AND MSS-WM IDENTIFY HIGH RISK WALDENSTRÖM MACROGLOBULINEMIA IN A REAL WORLD COHORT (292 Online Views)

First match: ... systems with molecular risk factors remain limited, particularly regarding the prognostic value of TP53 mutation and the recently proposed Modified Staging System for WM ...

U. Calis1, S. Yuksel2, M. K. Yuksel1, P. Topcuoglu1, I. Kuzu2, O. Arslan1, M. Ozcan1, T. Demirer1, S. Kocak Toprak1, M. Beksac3, G. Cengiz Seval1

1 Department of Hematology, Ankara University Faculty of Medicine, Turkey
2 Department of Pathology, Ankara University Faculty of Medicine, Turkey
3 Department of Hematology Istinye University, Ankara Liv Hospital, Turkey
Waldenström macroglobulinemia Real-world Practice

P56 | BASELINE IMMUNE PROFILE PREDICTS RESPONSE TO BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD MONOCENTRIC EXPLORATORY ANALYSIS (247 Online Views)

First match: ... sts host immune status is a key determinant. . Data on readily available immune biomarkers predicting response and resistance to BsAbs remain limited. This monocentric re ...

R. Della Pepa1, A. Leone1, L. Esposito1, G.L. D'Elia1, V. Cerbone2, M. Raia2, G. Scalia2, F. Pane1

1 Division of Hematology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Italy
2 Clinical and Experimental Cytometry Unit, Centre for Advanced Biotechnology Franco Salvatore, CEINGE Biotecnologie Avanzate, Naples, Italy

P52 | CILTACABTAGENE AUTOLEUCEL OUT-OF-SPECIFICATION MANUFACTURING OUTCOMES IMPROVE WITH EARLIER LINES OF THERAPY (221 Online Views)

First match: ... turing data were analysed to discern manufacturing outcome determinants, define biomarkers predictive of manufacturing success, and assess outcomes following OOS-driven r ...

R. Bowden1, H. Van Eeckhoutte1, G. Chow1, G. Choudhary1, L. Kallenbach1, V. Alegria1, M. Perciavalle2, J. Salmon2, J. Kang2, M. Mondon2, J. Vanak1, D. Ciccone1, P. Millili1, M. Onorata1, V. Plaks1, M. Merz3

1 Johnson & Johnson, USA
2 Legend Biotech USA Inc, Somerset, USA
3 Memorial Sloan Kettering Cancer Center, New York, USA
Ciltacabtagene autoleucel Multple Myeloma Manufacturing data

P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALiTEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA (252 Online Views)

First match: ... approach, was implemented to adjust for imbalances in 15 baseline covariates of prognostic significance. The relative effectiveness of teclistamab versus RWPC for respons ...

A. Perrot1, M. Kortüm2, R. Popat3, K. Uttervall4, M.V. Mateos5, K. Weisel6, K. Van Nimwegen7, J. Diels7, F. Ong7, R. Morano7, E. Rubio-Azpeitia7, P. Moreau8

1 Universite de Toulouse, France
2 University Hospital of Würzburg, Germany
3 University College London Hospitals NHS Foundation Trust, UK
4 Karolinska University Hospital, Stockholm, Sweden
5 Hospital Universitario de Salamanca, Spain
6 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7 Johnson & Johnson
8 University Hospital Hôtel-Dieu, Nantes, France
Multiple Myeloma RRMM Teclistamab

P17 | EARLY TREATMENT RESPONSE EVALUATION WITH WHOLE BODY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOCAL LESIONS (256 Online Views)

First match: ... ng early treatment response with WBMRI in NDMM seem to have both predictive and prognostic value.

I. Ntanasis-Stathopoulos1, V. Koutoulidis2, M. Gavriatopoulou1, M. Douka2, P. Malandrakis1, C. Filippatos1, V. Spiliopoulou1, F. Theodorakakou1, I. Katsadouros1, I. Solia1, P. Boutsikos1, M. Migkou1, N. Kanellias1, E. Eleutherakis-Papaiakovou1, E. Kastritis1, L.A. Moulopoulos2, M.A. Dimopoulos1|3, E. Terpos1

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece
2 1st Department of Radiology, School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens, Greece
3 Department of Medicine, Korea University, Seoul, South Korea
Whole-body magnetic resonance imaging NDMM Early response

P26 | CORRELATION OF THE CIRCULATING TUMOR CELLS AND R2-ISS SCORE IN NEWLY DIAGNOSED MYELOMA PATIENTS: RWE EXPERIENCE (235 Online Views)

First match: Background. Several prognostic stratifications, as second revision of the ISS (R2-ISS) score have been established in order to define high-risk patients (pts) with multip ...

N. Kecman1, M. Mitrovic1, A. Sretenovic1|2, Z. Bukumiric2|3, I. Tanovic1, N. Kraguljac Kurtovic1, J. Jovanovic1, J. Bila1|2

1 Clinic of Hematology University Clinical Center of Serbia, Belgrade, Serbia
2 Medical Faculty, University of Belgrade, Serbia
3 Institute of Biostatistics, Medical Faculty, University of Belgrade, Serbia
Multiple Myeloma Circulating tumor cells R2-ISS score

B03 | TRANSCRIPTOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCS) IN MULTIPLE MYELOMA REVEALS EGRESSION-ASSOCIATED PROFILE RELATED TO CTC BURDEN (404 Online Views)

First match: Background. CTCs have emerged as an important prognostic factor in newly diagnosed (ND) MM. However, the mechanisms of plasma cell (PC) egression from the bone marrow (BM ...

D. Bilek1|2|3, E. Radova2|3, V. Kapustova1|2, M. Warmuzova1|2, O. Venglar1|2, S. Nenarokov1|2, L. Broskevicova1|2, J. Vrana1|2, M. Kudelkova1|2, L. Muronova1|2, T. Popkova1|2, J. Mihalyova1|2, H. Plonkova4, M. Durante4, B. Diamond4, M. Simicek1|2, J. Bago1|2, D. Zihala1|2|3, T. Sevcikova1|2|3, O. Landgren4, R. Hajek1|2, T. Jelinek1|2|4

1 Department of Hemato-oncology, University Hospital Ostrava, Czech Republic
2 Department of Hemato-oncology, Faculty of Medicine, University of Ostrava, Czech Republic
3 Department of Biology and Ecology, Faculty of Science, University of Ostrava, Czech Republic
4 Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, USA
Circulating Tumor Cells NDMM New Prognostic Factors.

P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE (313 Online Views)

First match: ... and sustained MRD negativity are associated with longer survival and are strong prognostic clinical endpoints. PERSEUS (NCT03710603) evaluated subcutaneous Dara + VRd ind ...

P. Sonneveld1, P.. Moreau2, H. Einsele3, H. Quach4, P.J. Ho5, M. Beksac6, C. Hulin7, E. Antonioli8, X. Leleu9, S. Mangiacavalli10, A. Perrot11, M. Cavo12, A. Belotti13, A. Broijl1, H. Pei14, A. Sitthi-Amorn14, R.L. Carson14, P. Rodríguez-Otero15, M.A. Dimopoulos16, M. Boccadoro17

1 Erasmus MC Cancer Institute, Rotterdam, The Netherlands
2 University Hospital Hôtel-Dieu, Nantes, France
3 Universitätsklinikum Würzburg, Germany
4 University of Melbourne, Australia
5 Royal Prince Alfred Hospital, Sydney, Australia
6 Ankara University, Turkey
7 Hôpital Haut Lévêque, Pessac, France
8 University of Florence, Italy
9 CHU Poitiers, France
10 University of Pavia, Italy
11 Centre Hospitalier Universitaire de Toulouse, France
12 Bologna University, Italy
13 ASST Spedali Civili di Brescia, Italy
14 Johnson & Johnson, USA
15 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
16 National and Kapodistrian University of Athens, Greece
17 University of Turin, Italy
Minimal residual disease NDMM Therapy

P07 | CYTOKINE AND BONE MICROENVIRONMENT PROFILES REFLECT DISEASE STAGE AND OSTEOLYTIC INVOLVEMENT IN MULTIPLE MYELOMA (296 Online Views)

First match: ... 267), DKK-1 (p = 0.0202), and RANK (p = 0.0083). Conclusions. Several evaluated biomarkers showed significant correlations with the extent of skeletal involvement, suppor ...

J. Minarik1, J. Proskova2, V. Latal1, P. Krhovska1, T. Pika1

1 Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
2 Department of Clinical Biochemistry Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
Multiple Myeloma Osteolytic Involvement

P06 | FROM BENCH TO BEDSIDE: DRUG SENSITIVITY PROFILING TO OPTIMIZE THERAPY IN RELAPSED MULTIPLE MYELOMA (348 Online Views)

First match: ... increasingly important in this setting; however, the lack of robust predictive biomarkers limits individualized treatment selection. We evaluated a novel high-throughput ...

R. Cassano Cassano1|2, T. Martins3, D. Coffey4, G. Buda5, S. Galimberti5, L.M.A. Melillo2, R. Donnelly1, M. Kwok1, D. Green1, R. Banerjee1, K. Cicero1, T. Gooley1, R. Silbermann4, P. Becker6, A.J. Cowan1, D. Dima1

1 Fred Hutchinson Cancer Center, Seattle, USA
2 Policlinico Riuniti Foggia, Hematology Division, Italy
3 University of Washington, Seattle, USA
4 University of Miami Hospital and Clinics-UHealth Tower, USA
5 University of Pisa, Italy
6 OHSU Hospital, Portland, USA
Relapsed Multiple Myeloma CART Drug Sensitivity

B05 | SPATIAL IMAGING UNLOCKS THE POTENTIAL OF CHARTING MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE (293 Online Views)

First match: ... erences between bone marrow and EMD lesions. Using MICS, researchers stained 56 biomarkers across carefully prepared BM and EMD tissue samples from 5 newly diagnosed MM p ...

V. Desantis1, A. Andriano1, G. De Martino1, T. Düking2, O. Hartwig2, G. Ingravallo3, M. Biondo3, C. Botta4, R. Ria5, A. Vacca5, A.G. Solimando5

1 Department of Precision and Regenerative Medicine and Ionian Area-DiMePRe-J, Section of Pharmacology, University of Bari Aldo Moro, Italy
2 Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany
3 Department of General Surgery and Medical-Surgical Specialties, University of Catania, Italy
4 Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy
5 Internal Medicine "Guido Baccelli", University of Bari Aldo Moro, Italy
Spatial Imaging Plasma Cell Subclones Multiple Myeloma.

B04 | BLOOD-BASED RISK STRATIFICATION OF MYELOMA PATIENTS USING CIRCULATING TUMOR CELLS: RESULTS FROM THE EUROPEAN CTC CONSORTIUM (358 Online Views)

First match: Background. Circulating tumor cells (CTCs) are emerging biomarkers in multiple myeloma (MM) and may aid patient stratification when cytogenetic data is incomplete or unav ...

L. Bertamini1, D. Zihala2, I.V. Kostopoulos3, M. D’Agostino4, E. Martín-Sánchez5, J.J. Garcés Latre5, D. Hofste Op Bruinink1, N. Puig6, S. Zweegman7, G. Bertuglia4, P. Malandrakis8, T. Sevcikova2, T. Cupedo1, N.W.C.J. Van De Donk7, M.T. Cedena9, P. Musto10, I. Ntanasis-Stathopoulos8, O. Venglar2, M. Van Duin1, J.J. Lahuerta9, D. Rota Scalabrini11, O. Tsitsilonis3, T. Popkova2, J. Blade12, E. Zamagni13, M. Gavriatopoulou8, L. Muronova2, B. Van Der Holt1|14, P.. Moreau15, M.V. Mateos6, M. Galli16, E. Katodritou17, M. Stork18, A. Belotti19, P. Rousakis3, M. Borsky18, J. Corre20, M. Boccadoro21, M. Dimopoulos8, R. Hajek2, J. San Miguel5, P. Sonneveld1, F. Gay4, E. Terpos8, A. Broijl1, B. Paiva3, T. Jelinek2

1 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
2 Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Czech Republic
3 Department of Biology, School of Science, National and Kapodistrian University of Athens, Greece
4 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Italy
5 Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain
6 Hospital Universitario,Salamanca, Spain
7 Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, the Netherlands
8 Department of Clinical Therapeutics School of Medicine, National and Kapodistrian University of Athens, Greece
9 Hospital Universitario 12 De Octubre, Madrid, Spain
10 Department of Precision and Regenerative Medicine and Ionian Area,"Aldo Moro" University School of Medicine, and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy
11 Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Torino, Italy
12 Hospital Clínic de Barcelona, Spain
13 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Italy
14 HOVON Foundation, Rotterdam, the Netherlands
15 Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
16 Hematology and Bone Marrow Transplant Unit, Azienda Socio-Sanitaria Territoriale-Papa Giovanni XXIII, Bergamo, Italy
17 Department of Hematology, Theageneio Cancer Hospital, Thessaloniki, Greece
18 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic
19 Department of Hematology, ASST Spedali Civili di Brescia, Italy
20 Unité de Génomique du Myélome, University Hospital, IUCT-Oncopole, CRCT, Toulouse, France
21 European Myeloma Network, EMN
Circulating Tumor Cells Multiple Myeloma Plasma Cell Egression.

P75 | CURRENT STATUS OF REGISTRY OF MONOCLONAL GAMMOPATHIES - THE CZECH MYELOMA GROUP "REAL WORLD“ DATABASE (256 Online Views)

First match: ... ving novel therapies in the Czech Republic. Based on registry data, proprietary prognostic models for progression in MGUS and SMM have been developed. RMG data have also ...

V. Maisnar1, L. Pour2, I. Spicka3, J. Minarik4, T. Jelinek5, A. Jungova6, P. Pavlicek7, L. Roziakova8, J. Radocha1, A. Heindorfer9, M. Sykora10, P. Kessler11, L. Stejskal12, M. Wrobel13, J. Kopeckova14, K. Stankova15, L. Pospisilova15, R. Hajek5

1 4th Department of Medicine - Hematology, University Hospital, Hradec Kralove, Czech Republic
2 Internal Hemato-Oncology Clinic, University Hospital, Brno, Czech Republic
3 1st Medical Department – Clinical Department of Haematology, General Teaching Hospital, Prague, Czech Republic
4 Department of Hematooncology, University Hospital, Olomouc, Czech Republic
5 Department of Clinical Hematology, University Hospital, Ostrava, Czech Republic
6 Department of Hemato-oncology, University Hospital, Plzen, Czech Republic
7 Department of Clinical Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
8 Department of Clinical Hematology, University Hospital, Bratislava, Slovakia
9 Department of Hematology, Regional Hospital, Liberec, Czech Republic
10 Department of Clinical Hematology, Regional Hospital, Ceske Budejovice, Czech Republic
11 Department of Hematology, Regional Hospital, Pelhrimov, Czech Republic
12 Department of Hematology and Transfusion, Silesian Regional Hospital, Opava, Czech Republic
13 Department of Oncology, Regional Hospital, Novy Jicin, Czech Republic
14 Czech Myeloma Group, Brno, Czech Republic
15 Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
Real-world Practice Monoclonal Gammopathies RMG Working Group
Loading...
Searching...
1 - 23 of 23 items
Navigate
  • Home
  • Current issue
  • Early view
  • Archive
  • About Haematologica
  • Editorial Team
  • Our policies
  • Contact
For Authors
  • Author Guidelines
  • Submit Manuscript
  • Track Manuscript
For Reviewers
  • Reviewer Guidelines
  • Access Your Profile
  • Access Your Tasks
For Advertisers
  • Information For Advertising
Education
  • Review Articles
  • Guidelines Articles
Privacy
  • Cookie Policy
  • Newsletter Privacy Policy
  • Privacy Policy
More
  • Rights & Permissions

  • Web design
  • Development
Copyright © 2026 by the Ferrata Storti Foundation | Web design → | Development →
ISSN 0390-6078 print | ISSN 1592-8721 online